5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196)--clinical brochure.
D000293:Adolescent; D000328:Adult; D000577:Amides / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D001855:Bone Marrow Diseases / Q000139:chemically induced; D055598:Chemical Phenomena; D056486:Chemical and Drug Induced Liver Injury; D002621:Chemistry; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004285:Dogs; D005260:Female; D000882:Haplorhini; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D007223:Infant; D007938:Leukemia / Q000188:drug therapy; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy
D000577:Amides; D000970:Antineoplastic Agents; D007093:Imidazoles